Navigation Links
Cancer Mortality Increases With Cancer Cell Replikin Count
Date:12/4/2008

Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that the concentration of replikins, a new class of peptides in genomic proteins*, are quantitatively related to the mortality rate in human cancer of different cell types. No cancer cell genomic structure has previously been reported to be quantitatively related to mortality rate.

Boston, MA (PRWEB) December 4, 2008 -- Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that the concentration of replikins, a new class of peptides in genomic proteins*, are quantitatively related to the mortality rate in human cancer of different cell types. No cancer cell genomic structure has previously been reported to be quantitatively related to mortality rate.


     
The attached figure shows the relationship between the Replikin Count™ in the Replikin Peak Gene* and the percent mortality in human cancer: the higher the Replikin Count, the higher the percent mortality after 5 years.  Glioblastoma multiforme and non-small-cell lung cancer, the two cancer cell types with the greatest 5-year mortality rates in 2002 (98% and 91% respectively), are also the cell types which have the highest Replikin Counts (325 and 250 respectively).
 
The count in Glioblastoma Multiforme is 18 times higher than the counts in prostate and thyroid cancer which have the lowest Replikin Counts (20 and 15 respectively) as well as the lowest 5-year mortality rates (each approximately 2%). The quantitative relationship of Replikin count to mortality is also seen in the figure for other common cancers, which shows some deviations from an 'ideal' curve. For example, gastric cancer has a higher mortality rate than expected from its Replikin Count (ie shifted to the right), possibly because of the known difficulty of early detection of gastric cancer. Breast and urinary bladder cancer have lower mortality rates than expected from their Replikin Counts (ie shifted to the left), possibly because of the improvement in their early detection and prompt treatment.
 
To obtain these results, all cancer protein sequences published on PubMed were analyzed by histological cancer cell type by ReplikinForecast™ software. The Replikin Peak Gene (RPGene)* was identified in each cell type. The replikins in each RPGene were counted (Replikin Count = number of replikins per 100 amino acids).  The Replikin count of each RPGene then was compared in the different histological cancer cell types as shown in the attached Figure.
 
Replikin count has already been shown by Replikins, Ltd. to be related to rapid replication, disease outbreaks, and host mortality in viruses such as influenza and HIV, bacteria, malaria, and other infectious diseases*. The relationship between Replikin count and mortality in cancer parallels that found in H5N1 virus in humans and in Taura Syndrome Virus in shrimp.
 
The authors speculate that in low mortality cancers, it is possible that the immune system may be adequate to the number of invading units; but that the increased mortality rate in viruses and in cancer may reflect the overwhelming of host immune defenses by markedly increased numbers of viruses or of cancer cells produced in each case by increasing replikin concentration in the up-regulated Replikin Peak Gene.  An increase in number of cancer cells per unit time produced by rapid replication has been demonstrated in the laboratory in the case of glioblastoma multiforme brain cancer cells in tissue culture*. The quantitative relationship of Replikin Count to mortality rate has been demonstrated in the laboratory in four strains of lethal Taura Syndrome Virus in shrimp*.
 
These findings have diagnostic, therapeutic, and preventive applications. On the diagnostic side, 1) Oncolab, Inc.'s AMAS®Test, FDA permitted to market and Medicare approved, measures an anti-replikin antibody called the antimalignin antibody useful in the early detection of cancer. 2) Oncolab is now developing a test to determine the lethality of cancer specimens with the use of ReplikinsForecast™ to analyze the replikins in cancer cell protein sequences.  Encouraged by the proof of principle demonstration that synthetic replikin vaccines can be effective (91% of shrimp who received an oral synthetic replikin vaccine survived lethal Taura Syndrome virus challenge), synthetic replikin cancer vaccines are currently in development.
 
 
*References:
 
For published detailed antimalignin antibody data by Oncolab,Inc. and the replikins data of Replikins Ltd. studies,  see www.uspto.gov. For summaries see replikins.com under "Replikins Press" and OncolabInc.com.  Contacts: Oncolab, Inc. 617-536-9711; Replikins, Ltd. 617-536-0220.

# # #

Read the full story at http://www.prweb.com/releases/cancer/replikins/prweb1705354.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
2. Molecular Breast Imaging Identifies Occult Cancer
3. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
4. Prostate Cancer Stimulates Nerve Growth
5. Researchers discover new enzyme in cancer growth
6. International study supports new standard of treatment for women with advanced ovarian cancer
7. Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer
8. Broccoli compound targets key enzyme in late-stage cancer
9. Prostate cancer drug reduces testosterone levels in as little as 3 days
10. More High-Risk Women Preempt Breast Cancer
11. New breast imaging technology targets hard-to-detect cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Mortality Increases With Cancer Cell Replikin Count
(Date:2/12/2016)... ... 2016 , ... According to an article published February 4th on ... portion of hernia repairs throughout the United States. Commenting on this article, Beverly Hills ... this trend has not only been expected, but it seems to be a natural ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills ... recruit top students from U.S. universities who will draw from Siemens’ deep ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 ... ... Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... issue in the life cycle of pharmaceutical products, garnering increased attention from all ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a ... the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and ... intelligence (BI) to their small and medium business (SMB) clients. , ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... LONDON , Feb. 11, 2016 The ... current and future adoption patterns on the usage of ... include the following: - Timeframe of liquid ... types—CTCs, ctDNA, cfDNA and Evs—by organization type - Sample ... sample types: blood, saliva, stool, serum, and so on. ...
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
Breaking Medicine Technology: